Population Based Phase II Trial of Stereotactic Ablative Radiotherapy (SABR) for up to 5 Oligometastases: Preliminary Results of the SABR-5 Trial

被引：0
|
作者：
Olson, R. A. [1 ,2 ]
Jiang, W. [1 ,2 ]
Liu, M. C. [1 ,3 ]
Bergman, A. [3 ]
Schellenberg, D. [1 ,4 ]
Mou, B. [1 ,5 ]
Alexander, A. S. [1 ,6 ]
Carolan, H. [1 ,3 ]
Hsu, F. [1 ,7 ]
Miller, S. [1 ,2 ]
Atrchian, S. [8 ]
Chan, E. K. [1 ,3 ]
Ho, C. [1 ,9 ]
Mohamed, I. G. [1 ,5 ]
Lin, A. [1 ,5 ]
Berrang, T. [1 ,6 ]
Bang, A. [1 ,3 ]
Chng, N. [2 ]
Matthews, Q. [2 ]
Huang, V. [4 ]
Mestrovic, T. [6 ]
Hyde, D.
Lund, C. R. [1 ,4 ]
Pai, H. H. [1 ,6 ]
Valev, B. [1 ,6 ]
Lefresne, S. [10 ,11 ]
Tyldesley, S. [1 ,3 ]
机构：
[1] Univ British Columbia, Vancouver, BC, Canada
[2] BC Canc Prince George, Prince George, BC, Canada
[3] BC Canc Vancouver, Vancouver, BC, Canada
[4] BC Canc Surrey, Surrey, BC, Canada
[5] BC Canc Kelowna, Kelowna, BC, Canada
[6] BC Canc Victoria, Victoria, BC, Canada
[7] BC Canc Abbotsford, Abbotsford, BC, Canada
[8] BC Canc Agcy, Radiat Oncol, Kelowna, BC, Canada
[9] BC Canc Fraser Valley, Surrey, BC, Canada
[10] BC Canc Agcy, Vancouver, BC, Canada
[11] Univ British Columbia, Dept Surg, Div Radiat Oncol, Vancouver, BC, Canada
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2021年 / 111卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6
引用
收藏
页码：S4 / S4
页数：1
相关论文
共 50 条
  • [21] POLYMETASTATIC RECURRENCE-FREE SURVIVAL IN PATIENTS WITH REPEAT OLIGOMETASTASES ON THE SABR-5 TRIAL
    Liu, Wei
    Das, Subhadip
    Olson, Robert Anton
    Baker, Sarah
    Dunne, Emma
    Chang, Jee Suk
    Schellenberg, Devin
    Berrang, Tanya
    Hsu, Fred
    Jiang, Will
    Mou, Benjamin
    Lefresne, Shilo
    Tyldesley, Scott
    Liu, Mitchell
    RADIOTHERAPY AND ONCOLOGY, 2023, 186 : S29 - S29
  • [22] Letter of Response Regarding Adrenal SABR to the Article Published in the March 2024 Journal Publication: Prospective Longitudinal Assessment of Quality of Life after Stereotactic Ablative Radiotherapy for Oligometastases: Analysis of the Population-based SABR-5 Phase II Trial by Cruz-Lim et al.
    Irwin, A.
    Clarke, H.
    Ghafoor, Q.
    Watkins, S.
    CLINICAL ONCOLOGY, 2024, 36 (07) : e239 - e239
  • [23] A randomized phase III trial of stereotactic ablative radiotherapy for patients with up to 10 oligometastases and a synchronous primary tumor (SABR-SYNC): study protocol
    Palma, David A.
    Giuliani, Meredith E.
    Correa, Rohann J. M.
    Schneiders, Famke L.
    Harrow, Stephen
    Guckenberger, Matthias
    Zhang, Tina
    Bahig, Houda
    Senthi, Sashendra
    Chung, Peter
    Olson, Robert
    Lock, Michael
    Raman, Srinivas
    Bauman, Glenn S.
    Lok, Benjamin H.
    Laba, Joanna M.
    Glicksman, Rachel M.
    Nguyen, Timothy K.
    Lang, Pencilla
    Helou, Joelle
    Goodman, Christopher D.
    Mendez, Lucas C.
    van Rossum, Peter S. N.
    Warner, Andrew
    Gaede, Stewart
    Allan, Alison L.
    BMC PALLIATIVE CARE, 2024, 23 (01):
  • [24] Phase II trial of stereotactic ablative radiation (SAbR) for oligoprogressive kidney cancer.
    Hannan, Raquibul
    Christensen, Michael
    Garant, Aurelie
    Hammers, Hans J.
    Arafat, Waddah
    Courtney, Kevin Dale
    Bowman, Isaac Alex
    Cole, Suzanne
    Sher, David
    Ahn, Chul
    Timmerman, Robert D.
    Brugarolas, James
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [25] Phase II trial of stereotactic ablative radiation (SAbR) for oligometastatic kidney cancer.
    Hannan, Raquibul
    Christensen, Michael
    Robles, Liliana
    Christie, Alana
    Garant, Aurelie
    Desai, Neil Bipinchandra
    Hammers, Hans J.
    Arafat, Waddah
    Bowman, Isaac Alexander
    Cole, Suzanne
    Courtney, Kevin Dale
    Woldu, Solomon L.
    Bagrodia, Aditya
    Margulis, Vitaly
    Cadeddu, Jeffrey A.
    Choy, Hak
    Sher, David
    Brugarolas, James
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [26] Upfront Versus Delayed Systemic Therapy in Patients With Oligometastatic Cancer Treated With SABR in the Phase 2 SABR-5 Trial
    Baker, Sarah
    Lechner, Linden
    Liu, Mitchell
    Chang, Jee Suk
    Cruz-Lim, Ella Mae
    Mou, Ben
    Jiang, Will
    Bergman, Alanah
    Schellenberg, Devin
    Alexander, Abraham
    Berrang, Tanya
    Bang, Andrew
    Chng, Nick
    Matthews, Quinn
    Carolan, Hannah
    Hsu, Fred
    Miller, Stacey
    Atrchian, Siavash
    Chan, Elisa
    Ho, Clement
    Mohamed, Islam
    Lin, Angela
    Huang, Vicky
    Mestrovic, Ante
    Hyde, Derek, I
    Lund, Chad
    Pai, Howard
    Valev, Boris
    Lefresne, Shilo
    Arbour, Gregory
    Yu, Irene
    Tyldesley, Scott
    Olson, Rob A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : 1497 - 1506
  • [27] Dosimetric Predictors of Local Control after Stereotactic Ablative Radiotherapy (SABR) for Lung Tumors: A Secondary Analysis of a Phase II Prospective Trial of Individualized SABR (iSABR)
    Wu, Yufan Fred
    Lau, Brianna
    Fu, Jie
    Skinner, Lawrie
    Gensheimer, Michael
    Gee, Harriet
    Diehn, Maximilian
    Loo, Billy
    Chin, Alex
    Vitzthum, Lucas
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2022, 45 (09): : S16 - S16
  • [28] Phase II trial of pre-operative stereotactic ablative radiotherapy (SABR) in early-stage breast cancer
    Liveringhouse, C. L.
    Diaz, R.
    Ahmed, K. A.
    Lee, M. C.
    Czerniecki, B.
    Laronga, C.
    Khakpour, N.
    Weinfurtner, R. J.
    Rosa, M.
    Montejo, M. E.
    CANCER RESEARCH, 2019, 79 (04)
  • [29] Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
    Palma, David A.
    Olson, Robert
    Harrow, Stephen
    Gaede, Stewart
    Louie, Alexander V.
    Haasbeek, Cornelis
    Mulroy, Liam
    Lock, Michael
    Rodrigues, George B.
    Yaremko, Brian P.
    Schellenberg, Devin
    Ahmad, Belal
    Senthi, Sashendra
    Swaminath, Anand
    Kopek, Neil
    Liu, Mitchell
    Moore, Karen
    Currie, Suzanne
    Schlijper, Roel
    Bauman, Glenn S.
    Laba, Joanna
    Qu, X. Melody
    Warner, Andrew
    Senan, Suresh
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (25) : 2830 - +
  • [30] THE IMPACT OF ULTRA-CENTRAL TUMOUR LOCATION ON OUTCOMES IN PATIENTS WITH PULMONARY OLIGOMETASTASES: A SECONDARY ANALYSIS OF THE SINGLE-ARM PHASE II SABR-5 TRIAL
    Atmanspacher-Wirth, Hanna
    Zhao, Yizhou
    Schellenberg, Devin
    Clark, Haley
    Mou, Benjamin
    Liu, Mitchell
    Hsu, Fred
    Berrang, Tanya
    Atrchian, Siavash
    Bergman, Alanah
    Chng, Nick
    Matthews, Quinn
    Chang, Jee Suk
    Tyldesley, Scott
    Olson, Robert
    Baker, Sarah
    RADIOTHERAPY AND ONCOLOGY, 2024, 198 : S36 - S37
12345